4BV Stock Chart & Stats
€26.93
-€0.10(-0.37%)
At close: 4:00 PM EDT
€26.93
-€0.10(-0.37%)
Day’s Range― - ―
52-Week Range€24.90 - €29.34
Previous CloseN/A
Volume0.00
Average Volume (3M)20.00
Market Cap
€12.90B
Enterprise Value€14.13B
Total Cash (Recent Filing)€942.10M
Total Debt (Recent Filing)€3.04B
Price to Earnings (P/E)25.5
Beta0.67
Next Earnings
Feb 25, 2027EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.14
Shares Outstanding453,871,520
10 Day Avg. Volume30
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG Ratio4.32
Price to Book (P/B)7.08
Price to Sales (P/S)1.87
P/FCF Ratio14.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€32.91Price Target Upside22.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.49
Revenue Forecast (FY)€6.58B
Bulls Say, Bears Say
Bulls Say
Recurring Compliance DemandBureau Veritas serves compliance needs that are supported by regulation and customer standards, helping demand remain relevant across economic cycles. Recurring certification, surveillance, and inspection programs can also support repeat business, customer retention, and more predictable revenue over the coming quarters.
Steady Revenue And MarginsMulti-year revenue expansion combined with consistently solid profitability indicates a durable operating model rather than dependence on a single temporary gain. An operating margin near 14% provides earnings resilience and supports continued investment in the company’s global service network.
Strong Free Cash FlowHigh and improving free cash flow strengthens Bureau Veritas’s ability to fund operations, investment, and shareholder returns internally. Cash generation that remains well supported relative to net income also provides an important financial foundation, despite the company’s elevated leverage.
Bears Say
Rising LeverageHigher debt alongside declining equity reduces balance-sheet flexibility and increases financial risk. Even with strong cash generation, greater leverage can constrain capital allocation, make the business less resilient during weaker demand, and leave less room to absorb operating or financial shocks.
Declining Earnings Per ShareA significant decline in reported EPS indicates that per-share earnings have weakened despite the company’s steady revenue and generally solid profitability. If this trend persists, it could limit the pace of earnings compounding and reduce the benefit shareholders receive from operational growth.
Gross-margin VolatilityVolatility in reported gross margin makes the quality and repeatability of underlying profitability less certain. The unusually low 2025 level may reflect changes in business mix or classification, and continued inconsistency could make earnings performance harder to forecast over the next several quarters.
Bureau Veritas News
4BV FAQ
What was Bureau Veritas’s price range in the past 12 months?
Bureau Veritas lowest stock price was €24.90 and its highest was €29.34 in the past 12 months.
What is Bureau Veritas’s market cap?
Bureau Veritas’s market cap is €12.90B.
When is Bureau Veritas’s upcoming earnings report date?
Bureau Veritas’s upcoming earnings report date is Feb 25, 2027 which is in 117 days.
How were Bureau Veritas’s earnings last quarter?
Bureau Veritas released its earnings results on Jul 29, 2026. The company reported €0.68 earnings per share for the quarter, beating the consensus estimate of €0.67 by €0.01.
Is Bureau Veritas overvalued?
According to Wall Street analysts Bureau Veritas’s price is currently Undervalued.
Does Bureau Veritas pay dividends?
Bureau Veritas does not currently pay dividends.
What is Bureau Veritas’s EPS estimate?
Bureau Veritas’s EPS estimate is 0.9.
How many shares outstanding does Bureau Veritas have?
Bureau Veritas has 453,871,520 shares outstanding.
What happened to Bureau Veritas’s price movement after its last earnings report?
Bureau Veritas reported an EPS of €0.68 in its last earnings report, beating expectations of €0.67. Following the earnings report the stock price went up 2.859%.
Which hedge fund is a major shareholder of Bureau Veritas?
Currently, no hedge funds are holding shares in DE:4BV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bureau Veritas
Bureau Veritas S.A., a French company, delivers a broad spectrum of global testing, inspection, and certification (TIC) services. Its core mission is to guarantee that products, assets, and management systems meet either mandatory regulations or voluntary industry benchmarks. This is achieved through detailed inspection, analytical assessments, auditing, and certification processes, leading to comprehensive compliance reports. The company offers specialized laboratory and on-site testing for manufacturing and processing industries, alongside inspection services aimed at confirming product quality, quantity, and adherence to regulatory requirements. Additionally, it provides certifications for management systems, specific products, and even individuals. The firm's activities are organized into six distinct divisions: Marine & Offshore; Agri-Food & Commodities; Industry; Buildings & Infrastructure; Certification; and Consumer Products. Bureau Veritas caters to an exceptionally diverse clientele, spanning numerous sectors including automotive, transportation, construction, chemicals, agriculture, consumer products, food, marine, offshore, oil and gas, power, utilities, financial services, and governmental organizations. Established in 1828 and headquartered in Neuilly-sur-Seine, France, the company boasts an extensive international presence, operating approximately 1,600 offices and laboratories across about 140 countries.
4BV Stock 12 Month Forecast
Average Price Target
€32.91
▲(22.20% Upside)
Technical Analysis
bioMerieux
―
Eurofins Scientific
―
ID LOGISTICS
―
Sartorius Stedim Biotech
―
SPIE SA
―






